Nektar parlays alopecia readout into $374M follow-on: Public Equity Report

This week’s biggest follow-on went to Nektar, which raised $374 million after new Phase II data strengthened the case for rezpegaldesleukin in severe alopecia areata.

Nektar Therapeutics (NASDAQ:NKTR) rose 18% Monday after reporting that 16 additional weeks of treatment in the extension of its Phase II REZOLVE-AA trial produced further hair regrowth, enabling more patients to reach the company’s response threshold...